Cross-Border Cannabis Coalition Forms to Push US Federal Reform
New industry organization unites American and Canadian cannabis companies to accelerate federal policy changes, targeting banking and rescheduling priorities.
A new cross-border cannabis industry organization has emerged to coordinate lobbying efforts for federal policy reform, bringing together operators from both the United States and Canada under a unified advocacy umbrella. The formation represents a strategic shift toward international collaboration as the industry pushes for comprehensive federal changes that have stalled in Congress.
The timing reflects growing urgency around federal reform as state-legal cannabis companies continue operating under the constraints of federal prohibition. Banking restrictions, tax burdens under 280E, and interstate commerce limitations have created operational headwinds that particularly impact multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF). Canadian participation adds international perspective and resources from companies like Canopy Growth (CGC) and Tilray (TLRY) that have navigated federal legalization frameworks.
The coalition's formation comes as cannabis rescheduling discussions gain momentum within the Biden administration, with the DEA reviewing recommendations to move cannabis from Schedule I to Schedule III. This regulatory shift would eliminate 280E tax penalties and open banking access, potentially adding billions in value across the sector. However, the process has faced delays, creating frustration among operators watching quarterly margins compress under current restrictions.
Canadian companies bring valuable experience from their domestic legalization process, though their early enthusiasm for the US market has been tempered by regulatory complexity and capital constraints. Many scaled back US operations or divested assets entirely, but maintain strategic interest in federal reform that would enable direct market entry. The cross-border approach signals renewed confidence that policy changes are achievable with coordinated pressure.
The organization's launch underscores the industry's evolution from fragmented state-by-state advocacy toward sophisticated federal lobbying. With cannabis companies generating over $25 billion in annual US sales while operating under federal prohibition, the economic argument for reform has strengthened considerably. Success in advancing banking reform or rescheduling could trigger significant revaluations across cannabis equities, particularly for companies with strong balance sheets positioned to capitalize on expanded access to traditional financing and interstate expansion opportunities.